Upgrade to SI Premium - Free Trial

Form SCHEDULE 13G Transcode Therapeutics, Filed by: YA II PN, Ltd.

April 20, 2026 4:57 PM





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: Pursuant to the Standby Equity Purchase Agreement entered into on April 6, 2026 (the "Purchase Agreement") between YA II PN, Ltd. ("YA II") and TransCode Therapeutics, Inc. (the "Issuer"), YA II purchased a convertible promissory note on April 15, 2026 (the "Convertible Note") which may be converted by YA II, from time to time, into shares of Common Stock, par value $0.0001 per share ("Common Stock"), and may acquire additional shares of Common Stock in accordance with the Purchase Agreement. YA II is prohibited from acquiring any shares of Common Stock pursuant to the Purchase Agreement or the Convertible Note which when aggregated with all other shares of Common Stock then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the Common Stock outstanding. Calculation based on 1,018,740 shares of Common Stock, consisting of 916,968 shares of Common Stock outstanding as of April 3, 2026, plus an additional 101,772 shares of Common Stock that YA II may receive upon conversion of the Convertible Note.


SCHEDULE 13G




Comment for Type of Reporting Person: Pursuant to the Purchase Agreement, YA II purchased Convertible Note which may be converted by YA II, from time to time, into shares of Common Stock and may acquire additional shares of Common Stock in accordance with the Purchase Agreement. YA II is prohibited from acquiring any share of Common Stock pursuant to the Purchase Agreement or the Convertible Note which when aggregated with all other shares of Common Stock then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the Common Stock outstanding. Calculation based on 1,018,740 shares of Common Stock, consisting of 916,968 shares of Common Stock outstanding as of April 3, 2026, plus an additional 101,772 shares of Common Stock that YA II may receive upon conversion of the Convertible Note.


SCHEDULE 13G




Comment for Type of Reporting Person: Pursuant to the Purchase Agreement, YA II purchased Convertible Note which may be converted by YA II, from time to time, into shares of Common Stock and may acquire additional shares of Common Stock in accordance with the Purchase Agreement. YA II is prohibited from acquiring any share of Common Stock pursuant to the Purchase Agreement or the Convertible Note which when aggregated with all other shares of Common Stock then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the Common Stock outstanding. Calculation based on 1,018,740 shares of Common Stock, consisting of 916,968 shares of Common Stock outstanding as of April 3, 2026, plus an additional 101,772 shares of Common Stock that YA II may receive upon conversion of the Convertible Note.


SCHEDULE 13G




Comment for Type of Reporting Person: Pursuant to the Purchase Agreement, YA II purchased Convertible Note which may be converted by YA II, from time to time, into shares of Common Stock and may acquire additional shares of Common Stock in accordance with the Purchase Agreement. YA II is prohibited from acquiring any share of Common Stock pursuant to the Purchase Agreement or the Convertible Note which when aggregated with all other shares of Common Stock then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the Common Stock outstanding. Calculation based on 1,018,740 shares of Common Stock, consisting of 916,968 shares of Common Stock outstanding as of April 3, 2026, plus an additional 101,772 shares of Common Stock that YA II may receive upon conversion of the Convertible Note.


SCHEDULE 13G




Comment for Type of Reporting Person: Pursuant to the Purchase Agreement, YA II purchased Convertible Note which may be converted by YA II, from time to time, into shares of Common Stock and may acquire additional shares of Common Stock in accordance with the Purchase Agreement. YA II is prohibited from acquiring any share of Common Stock pursuant to the Purchase Agreement or the Convertible Note which when aggregated with all other shares of Common Stock then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the Common Stock outstanding. Calculation based on 1,018,740 shares of Common Stock, consisting of 916,968 shares of Common Stock outstanding as of April 3, 2026, plus an additional 101,772 shares of Common Stock that YA II may receive upon conversion of the Convertible Note.


SCHEDULE 13G




Comment for Type of Reporting Person: Pursuant to the Purchase Agreement, YA II purchased Convertible Note which may be converted by YA II, from time to time, into shares of Common Stock and may acquire additional shares of Common Stock in accordance with the Purchase Agreement. YA II is prohibited from acquiring any share of Common Stock pursuant to the Purchase Agreement or the Convertible Note which when aggregated with all other shares of Common Stock then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the Common Stock outstanding. Calculation based on 1,018,740 shares of Common Stock, consisting of 916,968 shares of Common Stock outstanding as of April 3, 2026, plus an additional 101,772 shares of Common Stock that YA II may receive upon conversion of the Convertible Note.


SCHEDULE 13G




Comment for Type of Reporting Person: Pursuant to the Purchase Agreement, YA II purchased Convertible Note which may be converted by YA II, from time to time, into shares of Common Stock and may acquire additional shares of Common Stock in accordance with the Purchase Agreement. YA II is prohibited from acquiring any share of Common Stock pursuant to the Purchase Agreement or the Convertible Note which when aggregated with all other shares of Common Stock then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the Common Stock outstanding. Calculation based on 1,018,740 shares of Common Stock, consisting of 916,968 shares of Common Stock outstanding as of April 3, 2026, plus an additional 101,772 shares of Common Stock that YA II may receive upon conversion of the Convertible Note.


SCHEDULE 13G




Comment for Type of Reporting Person: Pursuant to the Purchase Agreement, YA II purchased Convertible Note which may be converted by YA II, from time to time, into shares of Common Stock and may acquire additional shares of Common Stock in accordance with the Purchase Agreement. YA II is prohibited from acquiring any share of Common Stock pursuant to the Purchase Agreement or the Convertible Note which when aggregated with all other shares of Common Stock then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the Common Stock outstanding. Calculation based on 1,018,740 shares of Common Stock, consisting of 916,968 shares of Common Stock outstanding as of April 3, 2026, plus an additional 101,772 shares of Common Stock that YA II may receive upon conversion of the Convertible Note.


SCHEDULE 13G



YA II PN, Ltd.
Signature:/s/ David Gonzalez
Name/Title:David Gonzalez, General Counsel
Date:04/20/2026
YA Global Investments II (U.S.), LP
Signature:/s/ David Gonzalez
Name/Title:David Gonzalez, General Counsel
Date:04/20/2026
Yorkville Advisors Global, LP
Signature:/s/ David Gonzalez
Name/Title:David Gonzalez, General Counsel
Date:04/20/2026
Yorkville Advisors Global II, LLC
Signature:/s/ David Gonzalez
Name/Title:David Gonzalez, General Counsel
Date:04/20/2026
YAII GP, LP
Signature:/s/ David Gonzalez
Name/Title:David Gonzalez, General Counsel
Date:04/20/2026
YAII GP II, LLC
Signature:/s/ David Gonzalez
Name/Title:David Gonzalez, General Counsel
Date:04/20/2026
Mark Angelo
Signature:/s/ Mark Angelo
Name/Title:Mark Angelo
Date:04/20/2026
SC-Sigma Global Partners, LP
Signature:/s/ David Gonzalez
Name/Title:David Gonzalez, General Counsel
Date:04/20/2026

Categories

SEC Filings